Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Research Abstract Details
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Publishing Authors By Initials
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Journal Published:
PUBLICATION TYPE: Letter
Journal: International journal of hematology
VOLUME: 86
Page Numbers: 291-2
Journal Abbreviation: Int. J. Hematol.
ISSN: 0925-5710
DAY: 8
MONTH: Oct
YEAR: 2007
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 9111627
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
AFFILIATION:
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Int J Hematol
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder Related Publications